Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, decellularized human amniotic membrane was found to promote wound healing and reduce scar formation in rats with full-thickness skin defects, compared to traditional clinical treatments.

This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This project by the International Society of Hair Restoration Surgery aims to define best practices in hair restoration surgery but does not report new clinical findings.

In this study, increased Treg cell activity indicated by IL-10 and IL-15 was identified as a feature of ADTA, distinguishing it from AA and potentially explaining ADTA's more favorable prognosis.

This study characterized two siblings with hereditary vitamin D resistant rickets and a mutation in the vitamin D receptor, finding no immune-related disorders despite a defective T cell response to vitamin D.

This study identified a heterozygous de novo mutation in the ODC1 gene causing a new disorder characterized by overgrowth and developmental delay, and suggests that DFMO treatment may help manage elevated ODC activity and putrescine levels.

In this study, mutations in the vitamin D receptor were identified in Brazilian children with rickets and alopecia, leading to impaired receptor activation and reduced 24-hydroxylase expression.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that the opioid system, particularly via the delta opioid receptor, broadly regulates cutaneous mechanosensation, including touch, and suggests targeting this receptor could alleviate injury-induced mechanical hypersensitivity.

This study observed that patients with autism spectrum disorder have a higher risk of developing alopecia areata compared to those without ASD, suggesting a possible link between the two conditions.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

PRDX5 enzyme may contribute to alopecia areata by affecting oxidative stress and autoimmunity.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study introduced rPanglaoDB, an R package that facilitates the integration of public scRNA-seq datasets to effectively characterize rare cell types, exemplified by generating the first unbiased transcriptome profile of fibrocytes.

This study found that TLR3 activation in human keratinocytes enhances exosome biosynthesis and expression of hair follicle stem cell markers, suggesting a potential mechanism for tissue regeneration.

This study describes a patient with hereditary vitamin D resistant rickets (HVDRR) who, despite having a truncated vitamin D receptor, did not exhibit typical hair or skin abnormalities, suggesting possible compensation via interactions with other proteins.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This study found that applying both dehydrothermal treatment and carbodiimide crosslinking improved the mechanical properties of porcine acellular dermal matrix scaffolds without added cytotoxicity, suggesting potential applications in tissue engineering.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

In this study, DOP treatment improved hair regrowth in androgenetic alopecia by altering local steroid metabolism and follicular morphology.

This study used a novel HPLC-radiomatic flow scintillation system to measure 5α-reductase activity in dermal papillae from miniaturized hair follicles of the human occipital scalp, revealing significant variability in enzyme activity across samples.

This report presents the early development of the Lupus Foundation of America's LFA-REAL™ patient-reported instrument, designed to enhance evaluation of lupus disease activity by combining patient and physician assessments.